Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.81 EUR | -3.37% | -7.56% | +77.35% |
May. 15 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
May. 09 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+77.35% | 1.81B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target